Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Total Liabilities: 2015-2025

Historic Total Liabilities for Assembly Biosciences (ASMB) over the last 11 years, with Sep 2025 value amounting to $57.3 million.

  • Assembly Biosciences' Total Liabilities fell 22.83% to $57.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.3 million, marking a year-over-year decrease of 22.83%. This contributed to the annual value of $85.8 million for FY2024, which is 10.36% down from last year.
  • Per Assembly Biosciences' latest filing, its Total Liabilities stood at $57.3 million for Q3 2025, which was down 8.58% from $62.7 million recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' Total Liabilities registered a high of $95.7 million during Q4 2023, and its lowest value of $9.9 million during Q3 2023.
  • In the last 3 years, Assembly Biosciences' Total Liabilities had a median value of $71.9 million in 2025 and averaged $59.1 million.
  • As far as peak fluctuations go, Assembly Biosciences' Total Liabilities plummeted by 49.65% in 2022, and later surged by 648.96% in 2024.
  • Quarterly analysis of 5 years shows Assembly Biosciences' Total Liabilities stood at $22.1 million in 2021, then dropped by 13.56% to $19.1 million in 2022, then surged by 400.40% to $95.7 million in 2023, then decreased by 10.36% to $85.8 million in 2024, then dropped by 22.83% to $57.3 million in 2025.
  • Its Total Liabilities was $57.3 million in Q3 2025, compared to $62.7 million in Q2 2025 and $71.9 million in Q1 2025.